Showing results (371-380 of 463) with videos related to

Sort By:
Pageof 47
Clinical Pharmacology and Therapeutics|March 7, 2008
Influence of CYP3A4, CYP3A5, and ABCB1 genotype and expression on budesonide pharmacokinetics: a possible role of intestinal CYP3A4 expressionM Ufer, K Dilger, L Leschhorn, et al.
Alimentary Pharmacology & Therapeutics|September 3, 1998
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitisW Kruis, J W Brandes, S Schreiber, et al.
Gut|December 20, 2003
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitisT Mimura, F Rizzello, U Helwig, et al.
Alimentary Pharmacology & Therapeutics|April 23, 2002
Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitisT Mimura, F Rizzello, U Helwig, et al.
Neuropathology and Applied Neurobiology|August 7, 2019
Invited Review: The spectrum of age-related small vessel diseases: potential overlap and interactions of amyloid and nonamyloid vasculopathiesS Schreiber, A Wilisch-Neumann, F Schreiber, et al.
Frontiers in Behavioral Neuroscience|March 19, 2015
Benefits of adversity?! How life history affects the behavioral profile of mice varying in serotonin transporter genotypeCarina Bodden, S Helene Richter, Rebecca S Schreiber, et al.
AJNR. American Journal of Neuroradiology|March 25, 2022
Pulsatility Index in the Basal Ganglia Arteries Increases with Age in Elderly with and without Cerebral Small Vessel DiseaseV Perosa, T Arts, A Assmann, et al.
Alimentary Pharmacology & Therapeutics|July 14, 2005
Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohn's diseaseA Kasran, L Boon, C H Wortel, et al.
Deutsche Medizinische Wochenschrift (1946)|October 8, 2009
["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept]U Müller-Ladner, R Alten, A Heiligenhaus, et al.
Alimentary Pharmacology & Therapeutics|January 16, 2009
Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitisC Pena-Rossi, S Schreiber, G Golubovic, et al.
Pageof 47